Helsmoortel Hetty, Everaert Celine, Lumen Nicolaas, Ost Piet, Vandesompele Jo
Center for Medical Genetics, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Noncoding RNA Res. 2018 May 23;3(2):64-74. doi: 10.1016/j.ncrna.2018.05.001. eCollection 2018 Jun.
Prostate cancer is a heterogeneous malignancy, with clinical courses widely differing between indolent and aggressive lethal disease. This heterogeneity calls for a more personalized approach towards diagnosis, prognosis, treatment decision, monitoring and follow-up of patients. In this review, we discuss the possibilities and drawbacks of detecting RNA biomarkers in biological fluids to improve disease-specific survival and quality of life. In particular, we examine literature on long non-coding RNAs in blood and urine of prostate cancer patients. We thereby specifically focus on the need for standard operation procedures on many different levels, analytical validation, clinical validation, and assessment of clinical utility. We argue that thorough multi-step validation of putative biomarkers is necessary for successful translation into clinical prostate cancer care. Our recommendations may also prove useful to biomarker research in other cancers.
前列腺癌是一种异质性恶性肿瘤，其临床病程在惰性和侵袭性致命疾病之间存在很大差异。这种异质性要求对患者的诊断、预后、治疗决策、监测和随访采取更个性化的方法。在本综述中，我们讨论了在生物体液中检测RNA生物标志物以提高疾病特异性生存率和生活质量的可能性和缺点。特别是，我们研究了有关前列腺癌患者血液和尿液中长链非编码RNA的文献。我们特别关注在许多不同层面上对标准操作程序、分析验证、临床验证以及临床效用评估的需求。我们认为，对假定的生物标志物进行全面的多步骤验证对于成功转化为临床前列腺癌护理是必要的。我们的建议可能对其他癌症的生物标志物研究也有用。
